Trials / Completed
CompletedNCT02759250
A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)
A Pilot, Phase Ib Feasibility Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- argenx · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To characterize the safety profile of ARGX-110 administered as mono- or combination therapy to patients with NPC at various stages of its natural history (adjuvant vs. metastatic).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARGX-110 |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2018-04-25
- Completion
- 2018-06-01
- First posted
- 2016-05-03
- Last updated
- 2018-08-08
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT02759250. Inclusion in this directory is not an endorsement.